MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
76.70
-0.08
-0.10%
After Hours: 80.51 +3.81 +4.97% 19:00 05/12 EDT
OPEN
77.41
PREV CLOSE
76.78
HIGH
79.17
LOW
76.28
VOLUME
684.29K
TURNOVER
--
52 WEEK HIGH
80.99
52 WEEK LOW
36.93
MARKET CAP
3.87B
P/E (TTM)
-17.5234
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLNO last week (0505-0509)?
Weekly Report · 18h ago
Soleno Therapeutics’ Optimistic Earnings Call Highlights VYKAT XR Launch
TipRanks · 4d ago
Soleno Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Soleno Therapeutics Price Target Raised to $97.00/Share From $81.00 by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on Soleno Therapeutics, Raises Price Target to $97
Benzinga · 4d ago
Soleno Therapeutics Price Target Raised to $105.00/Share From $102.00 by Baird
Dow Jones · 4d ago
Soleno Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 4d ago
Soleno Therapeutics price target raised to $97 from $81 at Guggenheim
TipRanks · 4d ago
More
About SLNO
More
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Recently
Symbol
Price
%Change

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.